The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report.
Sarah Leary
Research Funding - Amgen
Julie R. Park
No relevant relationships to disclose
Joel M. Reid
No relevant relationships to disclose
Andrew T. Ralya
No relevant relationships to disclose
Sylvain Baruchel
Research Funding - Amgen
Bing Wu
Research Funding - Amgen
Ashish M Ingle
No relevant relationships to disclose
Charlotte H Ahern
No relevant relationships to disclose
Brenda Weigel
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose